Trial Profile
MUC-1 targeted Chimeric Antigen Receptor T Cells (CART) Therapy in Breast Cancer
Status:
Not yet recruiting
Phase of Trial:
Phase I
Latest Information Update: 16 Aug 2018
Price :
$35
*
At a glance
- Drugs Anti-MUC1 CAR-T cell therapy (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 16 Aug 2018 New trial record